We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Drug Delivery Method Used with Hollow Microstructures

By LabMedica International staff writers
Posted on 27 Sep 2017
A new method for producing microstructures was used to create hollow injectable microparticles that could be filled with liquid containing a therapeutic agent and then degraded over a programmable time period.

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) recently described a microfabrication method, termed StampEd Assembly of polymer Layers (SEAL), and used the method to create injectable pulsatile drug-delivery microparticles, pH sensors, and three-dimensional microfluidic devices that they could not produce using traditional three-dimensional printing. More...
SEAL allowed them to generate microstructures with complex geometry at high resolution, produce fully enclosed internal cavities containing a solid or liquid, and use potentially any thermoplastic material without processing additives.

For the current study, the investigators prepared microstructures in the shape of cups from PLGA (poly(lactic-co-glycolic acid)). By adjusting the degradation rate of the microparticle material, the cargo in the internal reservoir could be released at a desired time, ranging from a few days to two months.

PLGA has been successful as a biodegradable polymer because it undergoes hydrolysis in the body to produce the original monomers, lactic acid and glycolic acid. These two monomers under normal physiological conditions are by-products of various metabolic pathways in the body. Since the body effectively deals with the two monomers, there is minimal systemic toxicity associated with using PLGA for drug delivery or biomaterial applications.

The investigators reported in the September 15, 2017, issue of the journal Science that in mice, the particles released their contents in sharp bursts, without prior leakage, at nine, 20, and 41 days after injection.

"We are very excited about this work because, for the first time, we can create a library of tiny, encased vaccine particles, each programmed to release at a precise, predictable time, so that people could potentially receive a single injection that, in effect, would have multiple boosters already built into it. This could have a significant impact on patients everywhere, especially in the developing world where patient compliance is particularly poor," said senior author Dr. Robert Langer, professor of chemical engineering at the Massachusetts Institute of Technology.

Related Links:
Massachusetts Institute of Technology


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.